|
|
???tair.name??? >
???browser.page.title.author???
|
"dufour j f"???jsp.browse.items-by-author.description???
Showing items 1-6 of 6 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2022-09-09T04:21:23Z |
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
|
Lazarus J.V.; Mark H.E.; Villota-Rivas M.; Palayew A.; Carrieri P.; Colombo M.; Ekstedt M.; Esmat G.; George J.; Marchesini G.; Novak K.; Ocama P.; Ratziu V.; Razavi H.; Romero-G?mez M.; Silva M.; Spearman C.W.; Tacke F.; Tsochatzis E.A.; Yilmaz Y.; Younossi Z.M.; Wong V.W.-S.; Zelber-Sagi S.; Cortez-Pinto H.; Anstee Q.M.; Rouabhia S.; Ghazinyan H.; Iskandar N.J.; Trauner M.; Aghayeva G.; Carter F.; Sridharan K.; Al Mahtab M.; Francque S.; Kodjoh N.; Camacho R.M.; Anderson M.; Marques Souza de Oliveira C.P.; Mateva L.; Serme A.K.; Soares Martins A.A.; Swain M.G.; Komas N.P.; Zheng M.-H.; Jaramillo P.L.; Murillo O.A.; Mikolasevic I.; Vounou E.; Br?ha R.; Nlombi C.M.; Thiele M.; Perez M.; Su?rez M J.J.; Waked I.; Salupere R.; Desalegn H.; Yki-J?rvinen H.; Tsertsvadze T.; Sharvadze L.; Butsashvili M.; Awuku Y.A.; Papatheodoridis G.; Hunyady B.; Bjornsson E.S.; Duseja A.; Lesmana C.R.A.; Malekzadeh R.; Norris S.; Koike K.; Nersesov A.V.; Ochwoto M.; Jamal M.; Saparbu T.; Tolmane I.; Sayegh R.; Sheriff D.S.; Valantinas J.; Weber J.; Shawa I.T.; Tan S.-S.; Mart?nez V?zquez S.E.; Baatarkhuu O.; Lkhagvaa U.; Jadamba T.; Mohammed T.; Sudhamshu K.C.; Coppell K.; Onyekwere C.; Nikolova D.; Vesterhus M.; Al-Naamani K.; Hamid S.; M?ndez J.P.; Cabrera Cabrejos M.C.; Flisiak R.; Torres E.A.; Taheri S.; Sung K.-C.; Adela T.; Gheorghe L.; Sanai F.M.; Milovanovic T.; Bee Goh G.B.; Rac M.; Dassanayake A.; Osama S.B.; Elsanousi M.; Dufour J.-F.; JIA-HORNG KAO; Saidi D.; Treeprasertsuk S.; Koek G.; Labidi A.; Skrypnyk I.; AlKhatry M.S.; Sadirova S.; Bakieva S.; Sinkala E.; NAFLD policy review collaborators |
| 臺大學術典藏 |
2022-06-10T06:10:56Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 臺大學術典藏 |
2021-08-11T03:46:35Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 國立成功大學 |
2019 |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K. |
| 國立成功大學 |
2018 |
Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular Carcinoma
|
Lim, H.Y.;Merle, P.;Weiss, K.H.;Yau, T.;Ross, P.;Mazzaferro, V.;Blanc, J.-F.;Ma, Y.T.;Yen, C.J.;Kocsis, J.;Choo, S.P.;Sukeepaisarnjaroen, W.;Gerolami, R.;Dufour, J.-F.;Gane, E.J.;Ryoo, B.-Y.;Peck-Radosavljevic, M.;Dao, T.;Yeo, W.;Lamlertthon, W.;Thongsawat, S.;Teufel, M.;Roth, K.;Reis, D.;Childs, B.H.;Krissel, H.;Llovet, J.M. |
| 國立成功大學 |
2018 |
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis
|
Puoti, M.;Foster, G.R.;Wang, S.;Mutimer, D.;Gane, E.;Moreno, C.;Chang, T.T.;Lee, S.S.;Marinho, R.;Dufour, J.-F.;Pol, S.;Hezode, C.;Gordon, S.C.;Strasser, Strasser S.I.;Thuluvath, P.J.;Zhang, Zhang Z.;Lovell, S.;Pilot-Matias, T.;Mensa, F.J. |
Showing items 1-6 of 6 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
